Multiplexed molecular assays accelerate and broaden detection of antimicrobial resistance (AMR) genes by testing many targets in a single run. Clinical and public health laboratories increasingly pair multiplex PCR panels with sequencing-based workflows to shorten time to actionable results, inform therapy, and improve surveillance. Evidence from clinical evaluations supports these approaches: Erin L. Ledeboer Medical College of Wisconsin has published multi-center assessments of the FilmArray Blood Culture Identification Panel that demonstrate real-world operational benefits, and Josh Quick University of Birmingham has shown that portable nanopore sequencing can identify resistance determinants rapidly in outbreak and diagnostic contexts.
PCR-based multiplex panels
Platforms such as the FilmArray system, GenMark ePlex, Verigene, and Unyvero use multiplexed PCR or integrated sample-to-answer cartridges to detect common bacterial species and canonical resistance genes including mecA, vanA/vanB, and carbapenemase genes like blaKPC and blaNDM. These assays deliver rapid turn-around measured in hours rather than days, which can reduce inappropriate broad-spectrum antibiotic use and support antimicrobial stewardship. However, commercial panels cover a predefined set of targets and may miss novel or uncommon resistance mechanisms, so they complement rather than replace phenotypic susceptibility testing.
Sequencing and microarray approaches
Targeted and shotgun next-generation sequencing (NGS) expand detection beyond fixed panels, capturing diverse resistance genes and mobile elements. Oxford Nanopore Technologies platforms and Illumina workflows enable targeted amplicon sequencing or metagenomic analyses; researchers including Nicholas J. Loman University of Birmingham and Josh Quick University of Birmingham have advanced real-time sequencing applications in pathogen and AMR gene detection. DNA microarrays and hybridization-based assays also offer high multiplex capacity for surveillance laboratories. These methods provide comprehensive genotypic profiles that support outbreak investigation, track transmission across communities and environments, and feed into regional surveillance systems.
Faster, multiplexed detection influences clinical decision-making and public health responses, but implementation depends on local capacity, regulatory approvals, and cost. In low-resource settings, point-of-care multiplex systems can improve care if supported by supply chains and training, while sequencing-driven surveillance requires bioinformatics infrastructure. Choosing the right assay involves balancing speed, breadth, interpretive needs, and equity to ensure accurate detection of AMR genes and effective use of diagnostics in clinical and territorial contexts.